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Clostridioides difficile infection (CDI) is a toxin-mediated infection in the gut and a major
burden on healthcare facilities worldwide. We rationalized that it would be beneficial
to design an antibody therapy that is delivered to, and is active at the site of toxin
production, rather than neutralizing the circulating and luminal toxins after significant
damage of the layers of the intestines has occurred. Here we describe a highly
potent therapeutic, OraCAb, with high antibody titers and a formulation that protects
the antibodies from digestion/inactivation in the gastrointestinal tract. The potential of
OraCAb to prevent CDI in an in vivo hamster model and an in vitro human colon
model was assessed. In the hamster model we optimized the ratio of the antibodies
against each of the toxins produced by C. difficile (Toxins A and B). The concentration
of immunoglobulins that is effective in a hamster model of CDI was determined. A highly
significant difference in animal survival for those given an optimized OraCAb formulation
versus an untreated control group was observed. This is the first study testing the
effect of oral antibodies for treatment of CDI in an in vitro gut model seeded with a
human fecal inoculum. Treatment with OraCAb successfully neutralized toxin production
and did not interfere with the colonic microbiota in this model. Also, treatment with a
combination of vancomycin and OraCAb prevented simulated CDI recurrence, unlike
vancomycin therapy alone. These data demonstrate the efficacy of OraCAb formulation
for the treatment of CDI in pre-clinical models.
Keywords: Clostridioides difficile infection (CDI), immunotherapy of CDI, oral antibodies, formulation protecting
antibodies from digestion/inactivation, in vivo hamster model of CDI, in vitro human gut model of CDI
INTRODUCTION
Clostridioides difficile infection (CDI) is a leading cause of infectious antibiotic associated diarrhea
and a major burden on healthcare facilities worldwide (Wiegand et al., 2012; Lessa et al., 2015; Guh
et al., 2020). Disruption to the normal intestinal microbiota (e.g., by antibiotic exposure) is a key
risk factor for CDI, leading to loss of colonization resistance and creating a niche which C. difficile
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can exploit. CDI is a toxin mediated disease, with the primary
disease–causing factors identified as two large protein toxins,
Toxin A (TcdA) and Toxin B (TcdB) (Lyerly et al., 1985). A third
toxin which is likely to contribute to the disease (Gerding et al.,
2014), binary toxin (CDT), has been identified in a number of
epidemic strains, however, CDT itself does not appear to be
sufficient to cause CDI in animal models (Kuehne et al., 2014).
Currently, the standard treatment for CDI is antibiotic
therapy (use of metronidazole, vancomycin and more recently,
fidaxomicin), which has limited long-term efficacy, with
approximately 20–30% of patients experiencing recurrent disease
(Kelly, 2012) and fidaxomicin therapy resulting in ∼12% less
recurrences compared to vancomycin treatment (Mullane, 2014).
Alternative therapies directed at neutralizing TcdA and TcdB and
restoring the disrupted microbiome are in development. These
include antibody-based therapies, vaccines and fecal microbiome
transfer (FMT) and are summarized by Madoff et al. (2019).
Bezlotoxumab developed by Merck is the first monoclonal
antibody approved to prevent the recurrence of C. difficile
infection (Lee et al., 2017). It should be noted that despite
the promising benefits reported for FMT, the transmission of
an extended-spectrum beta-lactamase producing Escherichia coli
to two patients in two independent clinical trials has been
reported. Both patients developed bacteraemia and one died.
Therefore, the screening of FMT donors requires improvement
(DeFilipp et al., 2019).
It is likely that the host immune response is a critical factor
in recurrent disease, with naturally occurring toxin antibodies
shown to be protective against recurrent CDI (Kyne et al.,
2001). Human monoclonal antibodies (MAbs) against TcdA
and TcdB (actoxumab and bezlotoxumab) have been developed
(Babcock et al., 2006) and systemic administration of these
antibodies alongside standard of care therapy has been tested
in two large international multicentre, double blind randomized
placebo controlled trials (Wilcox et al., 2017). Administration
of bezlotoxumab led to significantly lower rates (∼11% less as
an absolute value compared to placebo) of recurrent disease
12 weeks after administration. Administration of actoxumab
alone showed no clinical benefit, and there was no additional
advantage of a combination of actoxumab and bezlotoxumab
compared with bezlotoxumab alone (Wilcox et al., 2017). Thus,
the therapeutic use of some MAbs against C. difficile toxins has
been shown to be beneficial in reducing cases of recurrent disease
when administered systemically. This MAb-based therapy has
been licensed for the prevention of recurrent CDI (when used
with standard of care antibiotics) and marketed as Zinplava.
Previously, we have described the use of systemically delivered
ovine polyclonal antibodies raised against toxoids of TcdA and
TcdB and against non-toxic recombinant fragments of TcdA
(TxA4) and TcdB (TxB4) as a potential treatment for severe CDI.
Importantly, these polyclonal antibodies can neutralize toxins
from several circulating C. difficile toxinotypes (0, III, V) (Roberts
et al., 2012; Maynard-Smith et al., 2014). In the present study, we
describe the potential of these antibodies for the management of
CDI when delivered as an oral therapy. The antibodies could be
used alongside standard of care antibiotics and in preference to or
in combination with FMT for the treatment of recurrence. This
oral therapy also has the potential to be used as a prophylactic in
high risk patients when entering a healthcare facility.
For toxin-mediated infections in the gut such as CDI, it would
be preferable to design an antibody therapy that is delivered
to and is active at the site of toxin production. The rationale
for delivering the antibodies orally is to target directly the
site of infection where TcdA and TcdB are released, rather
than neutralizing the toxins in the circulation and gut lamina
propria after significant damage of layers of the intestines has
occurred. Furthermore, especially when mucosal inflammation is
absent, only a negligible proportion of immunoglobulins injected
systemically may reach the lumen of the gut by transudation from
serum (Shearman et al., 1972). The development of several orally
delivered antibody-based therapies for CDI have been described
previously. These therapies include toxin-neutralizing antibodies,
for example, chicken IgY (Kink and Williams, 1998) and IgG in
bovine colostrum (Sponseller et al., 2015; Hutton et al., 2017).
Using platform technologies established by MicroPharm and
Public Health England (PHE), we have developed OraCAb, a
novel orally delivered ovine polyclonal antibody product targeted
toward C. difficile toxins. OraCAb has several advantages over
a therapy based on bovine colostrum. For example, there is
a constant supply of hyperimmune serum from immunized
sheep from which to prepare the product. In addition, OraCAb
contains highly efficacious toxin-neutralizing antibodies purified
from serum. Furthermore, bovine colostrum derived antibodies,
currently used for trials, are not protected against denaturation
and digestion by acidic gastric juice and pepsin in the stomach,
and trypsin and chymotrypsin in the small intestine. OraCAb
has been formulated to maintain the integrity of the antibodies
whilst the therapeutic is passing through the stomach and
small intestine. Unlike in intravenous administration, polyclonal
antibodies are not expected to cause a significant systemic
humoral immune response when taken orally. A recently
published study (Crowe et al., 2018) demonstrated that a small
amount of orally administered antibodies gain access to the
lamina propria and serum only when intestinal lesions are
in place, with antibody concentrations increasing with disease
severity. OraCAb is intended for treatment of mild to moderate
CDI where severe lesions are unlikely to occur. Neutralization
of TcdA and TcdB at the site of their production will eliminate
further damage in the colon and should minimize infiltration
of orally administered polyclonal immunoglobulins. The major
advantages of using polyclonal rather than MAbs against TcdA
and TcdB are the greater avidity of polyclonal antibodies, more
efficient neutralization of the very large toxin molecules and their
ability to neutralize a variety of toxinotypes of TcdA and TcdB.
This work describes the development strategy used to
formulate OraCAb and its potential to prevent CDI and CDI
recurrence in pre-clinical in vitro and in vivo models.
MATERIALS AND METHODS
Study Design
This study was designed to examine the protective efficacy of
an ovine antibody-based, orally delivered therapeutic for the
Frontiers in Microbiology | www.frontiersin.org 2 September 2020 | Volume 11 | Article 578903
fmicb-11-578903 September 22, 2020 Time: 12:7 # 3
Roberts et al. Orally Delivered Antibody Therapy for CDI
treatment of CDI, both in vitro and in the Golden Syrian hamster
model. The antibody formulation, OraCAb, was developed to
protect the antibodies during transit through the gut and to be
suitable for oral administration to hamsters. The formulations
were thoroughly tested in vitro before testing in vivo. The in vivo
model was employed to demonstrate the efficacy of a variety
of OraCAb formulations. The animals used in these studies
were Golden Syrian hamsters obtained from a UK Home Office
approved breeder (Envigo). The animals were 7–9 weeks old at
the start of an experiment, weighing 80–100 g.
The Project Licenses (30-3042 and P66F2D25B) enabling these
studies were approved by the Ethical Review Process of Public
Health England (PHE), Porton, Salisbury, United Kingdom and
the Home Office, United Kingdom. Animals were housed as
single sex pairs according to the Home Office Code of Practice
for the Housing and Care of Animals Bred, Supplied or Used
for Scientific Purposes, December 2014 and the NC3Rs (National
Centre for the Replacement, Refinement and Reduction of
Animals in Research).
The collection and use of stool samples from healthy adult
individuals in the in vitro human gut model was approved by
the University of Leeds School of Medicine Research Ethics
Committee (Ref: MREC15-070).
Production of Ovine Anti-TxA4 and
Anti-TxB4 Antisera and Antibodies
The recombinant antigens, TxA4 and TxB4 with sequences
obtained from VPI10463 strain, were expressed and purified
as described by Maynard-Smith et al. (2014). For antiserum
production, sheep were immunized at 0, 4, 8, 12, and
16 weeks with 250 µg of either antigen per dose as
described in Roberts et al. (2012). Pre-bleeds were collected
at week 0 and test bleeds collected at 6, 10, and 14 weeks.
A larger bleed was collected at 18 weeks when antibody toxin
neutralization titers were high. Prior to immunization, the
antigens were treated with formaldehyde, as previously described
(Maynard-Smith et al., 2014).
Purification of Bowman–Birk Protease
Inhibitor (BBI) From Lima Beans
BBI was produced at PHE from commercially available Lima
beans. Briefly, Lima beans were blended to a flour and defatted
with ethanol. BBI was purified through a combination of aqueous
acid extraction, ammonium sulfate precipitation, differential
solubilization in ethanol solutions, immobilized metal affinity
and anion exchange chromatography. Approximately 2.6 mg of
inhibitor, >95% pure, was obtained per gram of Lima beans.
The inhibitor was dialyzed against pH 7.5 HEPES (10 mM),
NaCl (100 mM), sterile filtered and freeze dried for inclusion
in OraCAb formulations, as required. Additional information on
BBI purification is available in Supplementary Materials.
Preparation of OraCAb Formulations
Series of OraCAb formulations used to optimize the anti-TxA4:
anti-TxB4 IgG ratio, IgG concentration and comparison of
protease inhibitors are given in Table 1.
TABLE 1 | OraCAb formulations used in in vivo studies.
Study OraCAb for in vivo studies (concentration mg/ml)
Anti-TxB4
IgG
Anti-TxA4
IgG
Protease Inhibitor (dried egg
white [DEW] or Bowman– Birk
inhibitor [BBI])
A (in vivo)
DEW (1:1 B:A) 75 75 DEW 60
DEW (3:1 B:A) 112.5 37.5 DEW 60
BBI (3:1 B:A) 112.5 37.5 BBI 10
B/D (in vivo)
No DEW 150 mg/ml 112.5 37.5 DEW 0
150 mg/ml 112.5 37.5 DEW 60
100 mg/ml 75 25 DEW 60
50 mg/ml 37.5 12.5 DEW 60
C (in vivo)
B only 112.5 0 DEW 60
3:1 B:A 112.5 37.5 DEW 60
1:1 B:A 75 75 DEW 60
Additional ingredients
Magnesium hydroxide (23.4 mg/ml), Dried aluminum hydroxide (26.4 mg/ml),
Methylparaben (E218) (2 mg/ml), Propylparaben (E216) (0.6 mg/ml), Glycine
(15 mg/ml), Simethicone (16.9 mg/ml), Sodium saccharin (0.4 mg/ml), and
Mannitol (21 mg/ml).
Anti-TxA4 IgG and anti-TxB4 IgG were formulated in 20 mM
sodium citrate buffer (pH 6.0) containing 153 mM NaCl (SCS).
After mixing the two antibodies in the required ratios (as
described in Table 1), all other constituents of the OraCAb
formulation were added and a stable suspension was prepared
by mixing with a ONE-ST-C laboratory scale propeller mixer
(Joshua Greaves & Sons Ltd, United Kingdom). The final volume
was adjusted with SCS. For the in vitro gut model studies,
antibodies formulated in SCS buffer only were used.
Nα-Benzoyl-DL-Arginine-p-Nitroanilide
(BAPNA) Assay for Activity of Trypsin
Inhibitors
The activity of the BBI and dried egg white (DEW) trypsin
inhibitors was determined by analysis of the reaction with
BAPNA as a substrate for trypsin. Samples of the BBI and DEW
were diluted in twofold series in a 96-well plate in quadruplet
rows. One hundred µl of porcine trypsin (Sigma) dissolved
in 1 mM HCl (Merck) at concentration of 0.0125 mg/ml was
added to triplicate samples. As a negative control 1 mM HCl
was added to one row of samples. Reagents in the experimental
plates were mixed by shaking for 15 min at room temperature.
One hundred µl of 6 mM BAPNA (Sigma) was added to each
well and incubated for 30 min at 37◦C. Fifty µl of 30% acetic
acid was added to each well and the absorbance was read at
410 and 690 nm using a POLARstar microplate reader (BMG
Labtech). Data were normalized by calculating A410-A690 in
Microsoft Excel for each well, and by subtracting the values for
corresponding samples without trypsin (1 mM HCl control).
Curves were plotted in Excel and EC50 values were generated
using a linear regression of data from the assay linear range.
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Stability of Immunoglobulins in OraCAb
to Simulated Gastric Fluid (SGF)
Simulated gastric fluid, pH 1.2 was prepared according to the
US Pharmacopeia and contained 2 g NaCl, 7 ml 37% HCl
and 3.2 g porcine pepsin (8000 U) (Sigma) made up to a liter
with water for irrigation. OraCAb was evaluated for stability
of immunoglobulins to SGF. SGF was mixed with OraCAb
formulation in different ratios (10% OraCAb, 20% OraCAb,
30% OraCAb, 40% OraCAb, and 50% OraCAb in SGF). The
mixtures were incubated for 2.5 h at 37◦C with gentle shaking
every 15 min. At the end of the incubation, pH was increased
by adding Phosphate Buffered Saline (PBS) to prevent further
protein digestion by the pepsin in SGF. Samples were then
analyzed by the toxin neutralization assay.
Toxin Neutralization Assay
Toxin neutralization assays were performed as described
previously (Roberts et al., 2012), with modification. Vero cells
were seeded at 9 × 103 cells per well in 96-well black microtiter-
plates (flat bottom, VWR) in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with Penicillin-Streptomycin
(100 U/ml and 0.1 mg/ml, respectively; Sigma), Glutamine
(2.0 mM; Sigma), HEPES (25 mM Sigma) and 10% Fetal Bovine
Serum (Sigma), and incubated for 24 h at 37◦C in a humidified
incubator under 5% CO2. Purified TcdA or TcdB proteins were
diluted in DMEM and prepared as 40 ng/ml or 400 pg/ml
dilutions, respectively. Suitably diluted oral formulation, anti-
TxA4 and anti-TxB4 antibodies were pre-mixed with either TcdA
or TcdB in a 96-well culture plate and 100 µl of the pre-mix
was transferred to the corresponding wells of the prepared plates
with Vero cells. Plates were incubated at 37◦C in 5% CO2 for
48 h. Each dilution was performed in duplicate. Forty µl of Cell-
Titer blue stain (Promega) was added to each well and incubated
for a further 4 h to determine cell viability. Fluorescence
was determined using a POLARstar microplate reader (BMG
Labtech) at λ590 nm. The cell survival percentage was calculated
in Microsoft Excel and plotted for each concentration using
GraphPad Prism. EC50 values were calculated using non-linear
regression (Sigmoidal fit, 4PL).
Bacterial Strains
Two C. difficile strains were used in this study.
The highly virulent VPI 10463 strain (ribotype 087/toxinotype
0) was obtained from the American Type Culture Collection
(ATCC 43255). Spores were prepared from this strain and used in
in vivo models as previously described (Roberts et al., 2012). The
VPI10463 strain is a high producer of both TcdA and TcdB that
makes the hamster model of CDI described below a very stringent
test for the efficacy of OraCAb.
The epidemic 027 210 strain (BI/NAP1/PCR ribotype
027/toxinotype III) was originally isolated during an outbreak of
CDI at the Maine Medical Centre (Portland, ME, United States)
in 2005 and was kindly supplied by Dr Robert Owens. Spores
were prepared from this strain and used in in vitro gut models
as previously described (Freeman et al., 2003). The strain used
in the in vitro studies was chosen as it is an example of an
epidemic, so-called ‘hypervirulent’ ribotype 027. Importantly, we
have a wealth of previous gut model data using this strain, so we
can make meaningful comparisons with previous data. This is
particularly helpful with a system such as this gut model which
is time consuming and labor intensive, so multiple experimental
repeats are not feasible.
Animal Model for C. difficile Infection
The Syrian hamster model was used as described previously
(Roberts et al., 2012; Maynard-Smith et al., 2014), using groups
of 10 animals (Figure 1). All animals received clindamycin, oro-
gastrically (o.g.), on day 0 (Sigma Aldrich; 2.0 mg in 0.2 ml
sterile water). On day 3, the animals in the test groups received
a C. difficile VPI 10463 spore challenge (o.g.; approximately
103 colony forming units in 0.2 ml DMEM). Animals in the
treatment groups were administered 0.75 ml of the appropriate
FIGURE 1 | Treatment design of the in vivo hamster model of CDI. Each experiment contains sentinel group (x4) that receive clindamycin only and an untreated
control group (x10) receiving clindamycin and challenge with C. difficile.
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OraCAb formulation 9 hrs post-challenge, using 18-gauge 76 mm
metal feeding tubes (Linton Instruments). For the following
4 days, these animals received OraCAb treatment twice a
day (0.75 ml/dose; 9 h interval between doses). A sentinel
group (4 animals) received clindamycin HCl, but no C. difficile
spore challenge and acted as a cross-infection control for the
experiment. Animals were not fasten prior dosing as per the
Home Office license under which this experiment was carried
out and they were fed ad libitum that would ensure that OraCAb
encounters similar conditions during gut transit at each dosing.
The animals were weighed daily and monitored 6 times
in a 24 h period for symptoms of CDI (diarrhoea, weight
loss, lethargy, tender abdomen, activity). Animals in advanced
stages of disease were euthanized. When surviving animals were
symptomless for 3 days, they continued to be weighed daily and
monitored twice daily.
Four different animal model studies were performed. Study A
consisted of four test groups of 10 animals; (1) Untreated, (2)
Received 150 mg/mL OraCAb formulation containing 3:1 anti-
TxB4 IgG (112.5 mg/ml): anti-TxA4 IgG (37.5 mg/ml) ratio with
BBI, (3) Received 150 mg/ml OraCAb formulation containing 1:1
anti-TxB4 IgG (75 mg/ml): anti-TxA4 IgG (75 mg/ml) ratio with
DEW (International Egg Products UK), (4) Received 150 mg/ml
OraCAb formulation containing 3:1 anti-TxB4 IgG: anti-TxA4
IgG ratio with DEW. Study B consisted of three test groups
of 10 animals; (1) Untreated, (2) Received 150 mg/ml OraCAb
formulation containing 3:1 anti-TxB4 IgG: anti-TxA4 IgG ratio
with DEW, (3) Received 150 mg/ml OraCAb formulation
containing 3:1 anti-TxB4 IgG: anti-TxA4 IgG ratio without
DEW. Study C consisted of four test groups of 10 animals;
(1) Untreated, (2) Received 150 mg/mL OraCAb formulation
containing 3:1 anti-TxB4 IgG: anti-TxA4 IgG ratio with DEW,
(3) Received 150 mg/mL OraCAb formulation containing 1:1
anti-TxB4 IgG: anti-TxA4 IgG ratio with DEW, (4) Received
112.5 mg/mL OraCAb formulation containing anti-TxB4 IgG
only with DEW. Study D consisted of four test groups of
10 animals; (1) Untreated, (2) Received 50 mg/ml OraCAb
formulation containing 3:1 anti-TxB4 IgG (37.5 mg/ml): anti-
TxA4 IgG (12.5 mg/ml) ratio with DEW, (3) Received 100 mg/ml
OraCAb formulation containing 3:1 anti-TxB4 IgG (75 mg/ml):
anti-TxA4 IgG (25 mg/ml) ratio with DEW, (4) Received
150 mg/ml OraCAb formulation containing 3:1 anti-TxB4 IgG
(112.5 mg/ml): anti-TxA4 IgG (37.5 mg/ml) ratio with DEW. The
compositions of the formulations are summarized in Table 1.
In vitro Gut Model for C. difficile Infection
Gut model studies were performed using a three-stage
continuous culture model of the colon. This model is validated
against sudden death patients for assessment of the colonic
environment and ecosystem (Macfarlane et al., 1998) and has
been developed for use with C. difficile (Freeman et al., 2003).
Three vessels were arranged in a weir cascade with each having
the pH controlled to model the proximal (Vessel 1, pH 5.5± 0.2),
transverse (Vessel 2, pH 6.2 ± 0.2), and distal colon (Vessel 3,
pH 6.8± 0.2). Vessel 1 had a volume of 280 ml, and vessels 2 and
3 had a volume of 300 ml. Temperature was maintained at 37◦C
and an anaerobic environment was retained by continuously
sparging with oxygen-free nitrogen. To maintain nutrient
availability, a nutrient dense medium was added to vessel 1 at a
rate of 13.2 ml/h by a peristaltic pump, and any overflow from
vessel 3 was collected as waste.
Four gut model experiments were performed to assess the
effect of OraCAb antibodies on C. difficile. Models were seeded
with stool samples from a minimum of three healthy individuals,
aged > 60 years, who had not received antibiotics in the previous
3 months. Stool samples were pooled, and slurries were produced
in a 1:10 w/v solution with pre- reduced PBS, equal amounts
of slurry were added to each vessel. The models had no further
intervention within the first 14 days to allow the bacterial
communities to equilibrate and stabilize. At day 14, and day 21,
a 1 ml aliquot of C. difficile spores (∼7 log10 cfu/ml, strain 210)
was added to vessel 1 of each model. To induce CDI, vessel 1 of
each model was treated with clindamycin (33.9 mg/l, four times
daily). It was at this point that the treatments for the models
diverge (Figure 2). Model 1; treatment with the placebo (sodium
citrate buffer, three times daily, 10 days) once spore germination
was detected [defined by an increase in total viable counts
(TVCs) compared to spore counts], Model 2; Treatment with
0.18 mg/ml anti-TxA4 IgG + 1.6 mg/ml anti-TxB4 IgG (three
times daily, 10 days) once spore germination was detected, Model
3; treatment with placebo once spore germination was detected,
then treatment with 0.18 mg/ml anti-TxA4 IgG + 1.6 mg/ml
anti-TxB4 IgG (three times daily, 10 days) once high toxin was
detected (cell cytotoxicity assay of three relative units), Model 4;
Treatment with vancomycin (125 mg/l four times daily, 7 days),
and 0.18 mg/ml anti-TxA4 IgG + 1.6 g/l anti-TxB4 IgG (three
times daily,∼35 days), once high toxin was detected.
Gut bacteria, C. difficile TVCs and spores were enumerated
three times a week during steady state, and daily thereafter
using selective agars for facultative and obligate anaerobes as
described previously (Chilton et al., 2014a). Samples for cytotoxin
detection were taken throughout the experiment and stored at
4◦C as described previously (Chilton et al., 2014a). Samples for
antimicrobial bioassay were taken post-antibiotic exposure and
stored at −20◦C prior to processing as described previously
(Chilton et al., 2014b).
Statistics
Hamster survival data at days 5 and 15 within each plot were
analyzed using the Gehan-Breslow test followed by the Holm–
Sidak method for pairwise comparison of the groups. Differences
between groups were considered statistically significant when
p < 0.05.
RESULTS
TcdA and TcdB Neutralization in vitro by
OraCAb Formulation
The amount of OraCAb ovine anti-TxA4 IgG and OraCAb
anti-ovine TxB4 IgG required to neutralize 1.0 ng of TcdA or
TcdB, respectively, was calculated using a Vero cell-based toxin
neutralization assay. To neutralize 1 ng of TcdA, 0.156 µg of anti-
TxA4 IgG were sufficient. For neutralization of 1 ng of TcdB 8 µg
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FIGURE 2 | In vitro gut model experimental design. Timeline for gut models, including equilibration of microbial community, induction of CDI and addition of placebo,
OraCAb antibodies or antibodies + vancomycin.
of anti-TxB4 IgG were required. The lower neutralizing capacity
of antibodies to TxB4 was taken into account in the design of the
protocols used in the hamster model and the in vitro gut model.
Previously, we determined that antibodies to both toxins were
required for protection in the hamster model when the antibodies
were administered systemically (Roberts et al., 2012). However,
others have shown that systemic administration of antibodies
against TcdA and TcdB do not improve the efficacy of treatment
of CDI compared to administration of anti-TcdB only in piglets
(Steele et al., 2013) and humans (Lee et al., 2017). Considering the
specificity of different CDI models, the in vivo studies described
here used formulations with anti-TxB4:anti-TxA4 ratios up to
3:1, while for the treatment of CDI in the in vitro human gut
model we used a ratio of approximately 9:1. Anti-TxA4 was not
abolished completely in the human gut model as in this study
antibodies were administered orally to act directly at the site
of infection, thus in an in vivo setup anti-TxA4 would protect
gut epithelium from further damage and prevent infiltration of
antibodies in the circulation.
Protection of Antibodies in the
Formulation From Enzymatic Digestion
in the GI Tract
To enable effective neutralization by OraCAb, the antibodies in
the formulation must be delivered intact to the large intestine.
Trypsin is the major proteolytic enzyme of the small intestine.
DEW and BBI, the latter which can be purified from Lima
beans, are two options that can be used as inhibitors of
trypsin in OraCAb formulation to protect the integrity of
the antibodies. Thus, we investigated the inhibition of human
trypsin in vitro by either DEW or BBI. The BBI inhibitor
was more potent, with approximately 15-fold less BBI being
required, compared to DEW, to inhibit the same amount of
human trypsin (Figure 3). This data together with available
information on concentration of trypsin in human GI tract
(Borgstrom et al., 1957) were used to inform levels of the two
inhibitors to be included in the OraCAb formulations used in the
in vivo experiments.
Protection of Antibodies in the
Formulation From Acid pH
The low pH in human gastric fluid (1.5–3.5) and the presence
of pepsin, would inactivate the proteins in the OraCAb
formulation by affecting their conformation and integrity.
OraCAb formulation contains antacids (magnesium hydroxide
and aluminum hydroxide), which have been used widely in
medicines for the treatment of dyspepsia, to protect the
antibodies and protease inhibitors from inactivation in the
stomach. The presence of antacids will also raise the stomach
pH leading to inactivation of pepsin. The antacids neutralize the
pH in the stomach once the OraCAb is taken. The aluminum
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FIGURE 3 | Inhibition of human trypsin with DEW and purified BBI determined by Nα-Benzoyl-DL-Arginine-p-Nitroanilide (BAPNA) colorimetric assay. Concentrations
of DEW and BBI that gave half-maximal inhibition of human trypsin (EC50) are given in the table.
hydroxide gel is also needed to maintain the higher pH while
the drug is present within the stomach and additional gastric
fluids are released. Antacid concentrations in OraCAb provide
a similar daily intake as that from dyspepsia medications. We
studied the dose of OraCAb that needed to be administered
orally to ensure full protection of the IgG in a simulated
gastric fluid (SGF). The data (Figure 4) show that OraCAb
mixed with the SGF at 3/10 v/v ratio was sufficient to
fully preserve the activity of the IgG. An example of the
protection of anti-TxA4 IgG in OraCAb from SGF is given in
Figure 4.
A Trypsin Inhibitor Appears to Preserve
OraCAb Activity in vivo
To determine whether OraCAb toxin neutralization can prevent
CDI in vivo, we used the Syrian hamster model. Animals
were given clindamycin orally 3 days before challenge and
then challenged with C. difficile spores via the oral route
on day 0. An untreated group acted as controls and a
sentinel group that received clindamycin, but no challenge,
was included to check for cross-contamination. Test groups
contained 10 animals and sentinel groups consisted of four
animals. The animals were then placed on one of the oral
therapeutic regimes until the end of day 4 (Table 1) and
monitored until day 15. Statistical analyses were performed
on day 5 (end of treatment) and day 15 (end of the study).
Survival results for each study are shown in Figure 5 and
Table 2.
We investigated the effects of inclusion of two different
protease inhibitors in the OraCAb formulation, BBI (10 mg/ml)
and DEW (60 mg/ml) (Figure 5). In study A, no significant
difference was observed between groups given formulations
containing DEW inhibitor and those receiving a formulation
containing BBI trypsin inhibitor (p = 1.0, Figure 5A), indicating
the benefit of these two inhibitors to be comparable in
the hamster model. In study B, disease progression was
rapid with no untreated animals surviving to the second
day post challenge. On day four the survival rate in the
group treated with OraCAb containing DEW was 50%, in
the absence of protease inhibitor it was 10% (Figure 5B).
By day ten there were no survivors in either group. In this
study there was a significant difference between the survival of
animals given OraCAb containing DEW and those treated with
OraCAb where DEW was omitted (p = 0.021) and a clinical
benefit of the addition of DEW can be observed during the
treatment period.
OraCAb Formulations Containing
Antibodies to Both TcdA and TcdB
Protect Hamsters From CDI
During the production and assessment of the ovine
antibodies to TxA4 and TxB4, we noted that the toxin
neutralizing capacity of ovine anti-TxB4 IgG was lower
than that of ovine anti-TxA4 IgG. In addition, in previous
studies we determined that antibodies to both toxins were
required for protection in the hamster model when the
antibodies were administered systemically (Roberts et al.,
2012). Therefore, we assessed the efficacy of different
OraCAb formulations containing different ratios of anti-
TxB4: anti-TxA4 IgG, as well as a formulation containing
anti-TxB4 IgG only.
All animals that received an OraCAb formulation containing
both anti-TxB4 and anti-TxA4 antibodies had a significantly
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FIGURE 4 | Stability of IgG (anti-TxA4) in OraCAb formulation in SGF. OraCAb was incubated for 2.5 h in SGF at different v/v ratios and full protection of the IgG was
found when the volume of OraCAb was 30% (3/10 ratio) or higher compared with the volume of the SGF. Around 50% of the IgG was found inactivated/degraded in
SGF containing 10 or 20% OraCAb. Concentrations of IgG in OraCAb that give half maximum inhibition of TcdA in a cell-based toxin neutralization assay (EC50) are
given in the table. The calculations were based on the concentration of IgG prior to mixing the formulations with SGF.
higher survival rate compared to untreated animals, whereas
those receiving anti-TxB4 IgG only did not (Figure 5C). In
study C (Figure 5C), 80% of the untreated animals succumbed
to CDI 5 days post-challenge. During this time interval, all
animals treated with OraCAb containing antibodies to both
toxins remained healthy. However, 40% of the group receiving
anti-TxB4 IgG only had succumbed to CDI. There was a
significant difference between the survival rates of animals
receiving 3:1 anti-TxB4: anti-TxA4 IgG and 1:1 anti-TxB4: anti-
TxA4 IgG compared to the control group (p = 0.018 and 0.049,
respectively). Animals receiving OraCAb containing antibodies
that neutralize TcdB only did not experience a statistically
meaningful clinical benefit over untreated animals (p = 0.30).
In study A (Figure 5A), all untreated animals succumbed to
CDI by day 5 post-challenge, in contrast to animals receiving
OraCAb, where all animals were protected from CDI during
this period. Fifty percent of the animals receiving OraCAb
with 1:1 anti-TxB4 to anti-TxA4 IgG ratio and 80% of animals
receiving OraCAb with 3:1 anti-TxB4 to anti-TxA4 IgG ratio
were protected and survived to the end of the study (p < 0.0001
compared to the untreated group). All OraCAb formulations
produced a significant clinical benefit relative to the untreated
control group. OraCAb, containing antibodies that neutralize
both TcdA and TcdB, appears to be protective in the hamster
model of CDI. The presence of antibodies to TcdA in the gut
appears to give increased efficacy of OraCAb in the hamster
model of CDI. A direct ELISA for detection of infiltrated
ovine IgGs in the sera from hamsters with CDI and treated
with OraCAb was developed (see Supplementary Material). No
presence of ovine IgG was detected in any of the tested 15 sera
(Supplementary Figure S2). Although the sera samples were
collected 10 days after the final OraCAb treatment, the high
sensitivity of the ELISA and the long half-life of ovine IgGs (more
than 10 days, Watson, 1992) strongly support the conclusion that
there was no significant systemic infiltration of ovine IgGs in
hamsters with CDI.
OraCAb Formulations Containing 3:1
Ratio of Anti-TxB4 to Anti-TxA4 IgG May
Be Superior to Those Containing 1:1
Ratios
For both studies A and C (Figures 5A,C), a higher survival rate
was observed for animals receiving the 3:1 anti-TxB4 to anti-
TxA4 IgG OraCAb formulation compared with those receiving
the 1:1 antibody formulation. In study A, 80% of the animals
receiving the 3:1 formulation survived to the end of the study
compared to 50% given the 1:1 ratio OraCAb. For study C,
percentage survival was 60 and 20% for the 3:1 ratio and the
1:1 ratio, respectively. Although survival data between the two
antibody ratios did not reach statistical significance in either
study, the data generated from both studies indicates a better
survival outcome and clinical benefit in the hamster model when
animals were treated with the OraCAb formulation with a ratio
of 3:1 anti-TxB4 to anti-TxA4 IgG. The statistical method used to
assess significance between different treatment groups is based on
the area under the survival curves. Thus, although a difference in
the survival rate of these two groups was observed after the end
of the treatment, significance between these two groups was not
achieved most likely due to their comparable outcome during the
treatment period.
OraCAb Administration Protects
Hamsters in a Dose-Dependent Manner
We investigated the dose dependency of OraCAb using
three different concentrations of antibody in a 3:1 ratio
of anti-TxB4:anti-TxA4 IgG. In study D, CDI progression
was rapid with no untreated animals surviving to the
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FIGURE 5 | Survival rates of hamsters after C. difficile challenge. Hamsters were challenged with C. difficile spores via the oral route on day 0, placed on one of the
oral therapeutic regimes until the end of day 4 and monitored until day 15. An untreated control group, receiving challenge only, was included for each experiment.
(A) Groups were treated with OraCAb containing different ratios of anti-TxB4: anti-TxA4 antibodies with either BBI or DEW as trypsin inhibitors. (B) Groups were
treated using OraCAb formulated with antibody concentration of 150 mg/ml at a 3:1 anti-TxB4: anti-TxA4 ratio in the presence or absence of DEW. (C) Groups were
treated with OraCAb containing different ratios of anti-TxB4: anti-TxA4 antibodies. The antibodies in OraCAb that contained anti-TxB4 IgG only were at the same
concentration as anti-TxB4 antibodies in the 3:1 anti-TxB4: anti-TxA4 formulation. All OraCAb formulations contained DEW. (D) Groups were treated with OraCAb
containing DEW and three different antibody concentrations (50, 100, or 150 mg/ml) at a fixed 3:1 anti-TxB4: anti-TxA4 ratio. The table shows the outcome of the
statistical analyses of the data.
second day post challenge (Figure 5D). Compared to the
untreated group, all OraCAb formulations provided a
significant increase in survival rate (50 mg/ml p = 0.035,
100 mg/ml p = 0.002, 150 mg/ml p < 0.0005). The 150 mg/ml
antibody OraCAb provided significantly better clinical benefit
compared to the 50 mg/ml antibody OraCAb formulation
(p = 0.016). No statistically meaningful differences were
observed between treatment groups receiving 100 mg/ml
and 150 mg/ml antibody OraCAb formulations (p = 0.30).
The data suggest that OraCAb containing greater than
50 mg/ml IgG is required for protection from CDI in
the hamster model.
OraCAb Antibody Instillation Prevents
Toxin Detection in an in vitro Gut Model
of CDI
A well validated and clinically reflective in vitro gut model of
CDI was used to investigate the efficacy of OraCAb instillation in
the presence of the normal human microbiota. The models were
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TABLE 2 | P-values calculated for different treatments in the in vivo model of CDI.
Study Comparison P-value end of study P-value end of treatment
A OraCAb DEW 3:1 B:A vs. untreated <0.001 <0.001
OraCAb BBI 3:1 B:A vs. untreated <0.001 <0.001
OraCAb DEW 1:1 B:A vs. untreated <0.001 <0.001
OraCAb DEW 3:1 B:A vs. OraCAb BBI 3:1 B:A 1.0 1.0
B OraCAb DEW 3:1 B:A vs. untreated 0.008 <0.001
OraCAb No DEW 3:1 B:A vs. untreated 0.003 0.001
OraCAb DEW 3:1 B:A vs. OraCAb No DEW 3:1 B:A 0.021 0.014
C OraCAb DEW 3:1 B:A vs. untreated 0.018 0.003
OraCAb DEW 1:1 B:A vs. untreated 0.049 0.002
OraCAb DEW anti-TxB4 only vs. untreated 0.30 0.18
D OraCAb 50 mg/ml IgG vs. untreated 0.035 0.004
OraCAb 100 mg/ml IgG vs. untreated 0.002 0.002
OraCAb 150 mg/ml IgG vs. untreated 0.008 <0.001
OraCAb 50 mg/ml IgG vs. OraCAb 150 mg/ml IgG 0.016 0.016
OraCAb 150 mg/ml IgG vs. OraCAb 100 mg/ml IgG 0.3 0.3
populated with a pooled fecal slurry and left to equilibrate before
simulated CDI was induced using clindamycin. Models were
treated with either (A) placebo (sodium citrate saline buffer),
(B) OraCAb antibodies alone, (C) placebo followed by OraCAb
antibodies (D) OraCAb antibodies alongside standard of care
(vancomycin). The OraCAb antibodies were formulated as 9:1
anti-TxB4 IgG: anti-TxA4 IgG in a sodium citrate saline buffer.
One of the benefits of using an in vitro system such as the gut
model in pre-clinical evaluation is that longitudinal trends (such
as C. difficile spore germination and toxin production) can be
followed in a way that is not possible clinically. In models A and
B it was specifically chosen to start instillation at the point of
spore germination in order to assess the impact of OraCAb as an
early intervention (to reflect the use of OraCAb as prophylaxis,
e.g., in prevention of recurrence). In Model C, it was instilled
from toxin detection (simulating the point at which a patient was
symptomatic), and in Model D alongside the ‘standard of care’
vancomycin. Thus we were able to gain data on the potential
efficacy of OraCAb administered in a variety of clinical scenarios.
Clindamycin exposure induced simulated CDI in all models
(Figure 6). Simulated CDI is defined by an increase in TVCs
over spore counts (indicating C. difficile spore germination and
vegetative cell proliferation), with concomitant high cytotoxin
detection. Instillation of placebo did not prevent C. difficile
vegetative growth or toxin detection (Figure 6A). TVCs peaked
at ∼6.5 log10 cfu/ml (spore counts ∼2 log10 cfu/ml) and
a peak toxin titer of 3 relative units was observed. Both
C. difficile vegetative growth and toxin production reduced,
before increasing again at the end of the experiment. Instillation
of OraCAb antibodies at the first sign of C. difficile spore
germination (increasing TVC over spore counts) did not affect
C. difficile vegetative growth (TVCs peaked at ∼6 log10 cfu/ml
with spores ∼2.5 log10 cfu/ml), but completely prevented the
detection of C. difficile cytotoxin (Figure 6B). Instillation of
placebo at the first sign of spore germination followed by
instillation of OraCAb antibodies at simulated CDI (high toxin
detection) led to a rapid decrease in detectable toxin (2 days after
peak toxin compared to 5 days after peak toxin in the placebo
treated model). No further toxin was detected during OraCAb
antibody instillation, apart from a low level titer of 1 on the final
day of experiment. This was despite a second increase in TVC
counts compared to spores, indicating prolonged vegetative cell
proliferation (Figure 6C).
OraCAb Antibody Instillation Alongside
Standard of Care (Vancomycin) Prevents
Simulated Recurrent CDI in an in vitro
Gut Model of CDI
Instillation of OraCAb antibodies alongside vancomycin caused
rapid reduction in C. difficile vegetative cells and cytotoxin levels,
as has been observed previously when vancomycin is used to
treat simulated CDI in the gut models (Freeman et al., 2005;
Baines et al., 2008; Chilton et al., 2012, 2014b; Crowther et al.,
2015). No further toxin was detected throughout the experiment
(Figure 6D). Importantly, in model 4 (Figure 6D), recurrent
C. difficile vegetative cell growth was observed post vancomycin
instillation. It would be expected that this would be accompanied
by cytotoxin production (simulated recurrent disease) as has been
observed previously (Chilton et al., 2012, 2014b; Crowther et al.,
2015), however, with the installation of the OraCAb antibodies,
no toxin was detected.
OraCAb Antibody Instillation Did Not
Affect Gut Microbiota Populations in an
in vitro Gut Model of CDI
Instillation of antibodies did not affect microbiota populations,
the dynamics of which were similar in all experiments and
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FIGURE 6 | Mean C. difficile total viable counts (log10 cfu/ml), spore counts (log10 cfu/ml) and cytotoxin titer [relative units (RU)] in vessel three of the in vitro gut
model. (A) – Model 1 (placebo); (B) – Model 2 (antibodies); (C) – Model 3 (placebo + antibodies); (D) – Model 4 (vancomycin + antibodies). The limit of detection is
1.22 log10 cfu/ml for total viable counts and 1.52 log10 cfu/ml for spore counts; horizontal dotted lines.
to those from previously reported in vitro gut model studies
(Freeman et al., 2005; Baines et al., 2008; Chilton et al., 2012,
2014a; Crowther et al., 2015). The results from models 1 and 2,
receiving placebo and antibody are shown here (Figure 7).
Although some variation was observed between individual
models, clindamycin instillation had similar effects to those
reported previously in the in vitro gut model of CDI, causing
declines in Bifidobacterium species (∼6 log10 cfu/ml to below the
limit of detection), and Lactobacillus populations (∼2–4 log10
cfu/ml), and increases in lactose fermenting Enterobacteriaceae
(∼2 log10 cfu/ml) and Enterococcus species (∼4 log10 cfu/ml).
Recovery following clindamycin exposure was similar regardless
of whether models were exposed to antibodies or placebo. These
data provide an important indication that the effects of OraCAb
on humanized gut microbiota is minimal.
These results highlight the protective capacity provided by an
orally delivered ovine polyclonal antibody formulation designed
to neutralize both TcdA and TcdB. The formulation protects
hamsters from CDI and the antibodies have been shown to
neutralize TcdA and TcdB in the human gut model. The
antibodies can be used alongside standard of care antibiotics and
they do not have a deleterious effect on the microbial flora.
DISCUSSION
CDI remains a problem within healthcare systems of the
developed (Lessa et al., 2015) and the developing world
(Chaudhry et al., 2017). It is interesting that at present
approximately 60% of CDI cases are defined as ‘community-
acquired,’ but this leads to further cases needing hospitalization
(Ofori et al., 2018; Public Health England, 2019). Even with
effective therapy, recurrent infection is common, ranging from
20% after initial infection to 60% after multiple prior recurrences
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FIGURE 7 | Mean viable counts of selected microbiota communities in vessel three of the in vitro gut model. (A) – Model 1 (placebo); (B) – Model 2 (antibodies). The
limit of detection is 1.22 log10 cfu/ml; horizontal dotted line.
(McFarland et al., 1999), suggesting that antibiotic treatment has
failed to eradicate C. difficile and/or exacerbated the dysbiosis
that initially allowed the bacterium to proliferate and produce
toxin. Therefore, additional therapeutic options are required for
use when antibiotic treatment alone fails (Jawa and Mercer,
2012). For example, a combined standard of care antibiotic and
systemically administered bezlotoxumab, a MAb against TcdB,
has been proved to be clinically effective in the prevention of
recurrent CDI (Wilcox et al., 2017).
Previously we described development of a therapeutic for CDI
based on the administration of ovine polyclonal antibodies to
novel, non-toxic recombinant antigens, TxA4 and TxB4, based
on TcdA and TcdB. This was the first use of ovine serum
antibodies in the treatment of CDI. These antibodies potently
neutralize TcdA and TcdB in both in vitro cell assays and in an
in vivo hamster model for CDI (Maynard-Smith et al., 2014). In
the present study we show that these ovine antibodies can also be
formulated for oral delivery and can act as an effective therapeutic
for CDI. We also show in an in vitro human gut model that
the antibodies prevent the detection of toxin activity during
simulated recurrent CDI. Unlike antibiotics, OraCAb antibodies
do not have a deleterious effect on the human gut flora. This is the
first study to describe the use of orally delivered ovine polyclonal
IgG for the treatment of CDI.
To our knowledge, this is the first use of an in vitro gut model
seeded with a human fecal inoculum to test the effects of oral
antibodies for C. difficile infection. Treatment with clindamycin
and vancomycin, resulted in a loss of colonization resistance
and led to CDI, as previously identified in gut model studies
(Chilton et al., 2014a; Crowther et al., 2015). OraCAb repeatedly
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neutralized C. difficile cytotoxin, Figure 6C demonstrating that
within 48 h the toxin produced was neutralized from a titer of
3 RU to undetectable. Additionally, consistent treatment with
OraCAb, prevented the detection of C. difficile cytotoxin for
greater than 48 h (Figures 5B–D). Of note, although OraCAb
prevented the detection of cytotoxin, it did not prevent the
growth and spore germination of C. difficile itself. OraCAb has
been developed to reduce the toxin burden in the gut and thus it
was not expected to have anti-C. difficile properties. As CDI is a
toxin mediated disease (Lyerly et al., 1985), these results suggest
that OraCAb would be beneficial, as a potential prophylaxic,
alongside standard of care treatments for CDI.
Passive immunization, using both polyclonal (mostly of
bovine colostrum and chicken egg origin) and MAbs, to protect
against CDI has been studied extensively in animal models
(Kink and Williams, 1998; Roberts et al., 2012; Maynard-Smith
et al., 2014; Sponseller et al., 2015; Pizarro-Guajardo et al.,
2017). Hyperimmune ovine serum, unlike bovine colostrum,
can be continually supplied and requires only immunization
boosts at certain time intervals. Polyclonal antibodies have several
advantages over MAbs. Firstly, they are cheaper to produce,
and secondly, they bind to several epitopes on their antigen,
increasing the neutralizing efficacy of the therapeutic against
sequence variants, such as those observed in TcdA and TcdB
of C. difficile. Recently, Cole and co-workers demonstrated that
polyclonal sera to both TcdA and TcdB when tested in an in vitro
toxin neutralization assay, displayed greater activity against the
toxins than equivalent concentrations of individual MAbs (Cole
et al., 2019). Animal-derived polyclonal antibodies have the
disadvantage of inducing an immune response in the recipient
when delivered systemically and thus the number of doses will be
limited. In severe disease, where therapeutic options have been
exhausted, one or two doses may be all that is required to alleviate
symptoms. Recently, bezlotoxumab, a MAb-based therapy, has
been licensed for use in the prevention of recurrent CDI (Wilcox
et al., 2017). However, CDI is an infection of the large intestine
where the virulence factors act on the intestinal epithelium
and therefore the oral delivery of an immunotherapeutic at the
site of toxin production and action would be advantageous.
Oral administration would be the preferable route for non-
severe and/or recurrent CDI allowing repeated treatment to take
place due to lack of adverse humoral responses in circulation
as indicated by clinical trials with orally delivered polyclonal
antibodies against TNFα (AVX-470) for treatment of ulcerative
colitis (Harris et al., 2016), a disease which is also associated with
severe colon inflammation. Zhang et al. (2015) have argued that
the requirement for epithelial disruption to allow transport of
systemic antibodies to the site of infection (i.e., the gut lumen)
is actually an advantage as it provides a constant source of
antibodies over time to defend against future infections. Indeed,
this is correct in severe CDI when systemic administration of
antibodies against C. difficile toxins would have no alternative.
There have been a few clinical trials in which bovine
antibodies have been administered orally in healthy or challenged
individuals (Jasion and Burnett, 2015). Data from these trials
show survival of orally administered immunoglobulins through
the digestive tract in humans to be between 0.01 and 20%. These
observations along with our data that addition of a protease
inhibitor to the formulation led to significant improvement in
survival of animals during the treatment (Figure 5B) clearly
demonstrate the need for protection of immunoglobulins from
digestion and/or inactivation in the GI tract. The OraCAb
formulation that we report here protects the proteins in this
formulation from degradation/inactivation by low pH in gastric
fluid and from proteases during transit from oral administration
to the large intestine (Figures 2, 3). Two protease inhibitors
were investigated for inclusion in OraCAb. BBI is a highly
purified trypsin and chymotrypsin inhibitor from Lima beans.
It can pass through the stomach and small intestine without
major degradation (Clemente et al., 2011). DEW contains
several protease inhibitors (Saxena and Tayyab, 1997). It is
known that some proteolytic inhibitors have a feedback control
of proteolytic enzyme secretion in humans (Liener et al.,
1986) and also in animals, e.g., rats (Geratz and Hurt, 1970).
Some trypsin/chymotrypsin inhibitors stimulate secretion of
proteolytic enzymes into small intestines (e.g., Bowman-Birk
Inhibitor, 4,4′-diamino-diphenylamine), however, others like
p-aminobenzamidine does not seem to have significant effect
on secretion of trypsin and chymotrypsin in small intestine in
rats (Geratz and Hurt, 1970). DEW has not been tested for
effect on secretion of proteases in small intestines. However,
the quantity of trypsin/chymotrypsin inhibitors in OraCAb has
been calculated based on data for concentrations of these two
enzymes in human duodenum during digestion of standard
meal (Worning and Müllertz, 1966) with an excess to allow for
possible increased secretion of these proteases. Our in vivo data
(Figure 5A) showed that the 2.5-fold higher potency of BBI
in the formulation compared to that of DEW did not make
significant difference in survival of the hamsters. The fact that
increasing the potency of trypsin/chymotrypsin inhibitors with
a feedback control did not affect the survival rates demonstrate
that the concentration of 60 mg/ml DEW was sufficient to ensure
protection from proteolytic enzymes in the hamster model of
CDI even if a similar feedback control in release of proteolytic
enzymes takes place in presence of DEW. Thus, subsequent
experiments were performed with OraCAb containing DEW
which considerably reduces the manufacture cost of OraCAb.
Over recent years there has been much conjecture over
the roles of TcdA and TcdB in CDI. Laboratory-derived TcdA
and TcdB gene knock-out mutants, when tested in the gold
standard hamster model, have given conflicting results. Using
survival data, Lyras et al. (2009) proposed that TcdB was the
key virulence factor. However, Kuehne et al. (2010, 2014) and
Carter et al. (2015) have both demonstrated that either TcdA
or TcdB can cause fulminant disease in the hamster infection
model. Furthermore, in previous studies, we have shown that
antibodies which neutralize specifically either TcdA or TcdB
are both required to provide protection against CDI in the
hamster when given systemically. In vitro assays demonstrated
no neutralization of TcdA by anti-TcdB antibodies and vice
versa (Roberts et al., 2012; Maynard-Smith et al., 2014). In this
study we addressed if both antibodies are required for treatment
of CDI in a hamster model when the therapy is given orally,
and neutralizing antibodies are delivered directly to the site of
Frontiers in Microbiology | www.frontiersin.org 13 September 2020 | Volume 11 | Article 578903
fmicb-11-578903 September 22, 2020 Time: 12:7 # 14
Roberts et al. Orally Delivered Antibody Therapy for CDI
infection. Our data showed that antibodies against TcdB alone
did not significantly protect from CDI (Figure 5C). This finding
suggests that TcdA is important in the pathogenesis of CDI, at
least in the hamster model, when a highly toxigenic challenge
strain is employed. Apart from their cytotoxic effects on the
epithelium of the large intestine, TcdA and TcdB have been
shown to be pro-inflammatory by eliciting cytokine release, with
TcdA causing a greater pro-inflammatory reaction than TcdB
(Yu et al., 2017). Therefore, the neutralization of both toxins
might provide better protection of the gut epithelium. The strong
inflammatory response induced by TcdA (and TcdB) triggers
the release of inflammatory mediators from intestinal epithelial
cells which leads to intestinal barrier dysfunction (Hansen et al.,
2013; Yu et al., 2017). Thus, TcdA may play a pivotal role in
the toxicity of TcdB and the severity of CDI by facilitating
systemic entry of both toxins. Neutralization of both toxins at
the site of their production might reduce gut damage, decreasing
extra-intestinal transit of toxins and systemic effects of severe
CDI. Kink and Williams (Kink and Williams, 1998), using orally
delivered antibodies derived from eggs, showed that antibodies
to both toxins were required to prevent mortality in the hamster
model, supporting the results obtained in this study. However,
Hutton et al. (2017) suggest that the oral administration of bovine
hyperimmune colostrum, containing neutralizing antibodies to
TcdB only, is effective in the treatment or prevention of CDI.
There were several differences between the current study and
the studies undertaken by Hutton and colleagues. For example,
in the latter study, the mouse model of CDI was employed and
run for 4 days post-challenge during which period mice were
given hyper-immune bovine colostrum as the antibody source.
A ribotype 027 C. difficile strain was used to challenge the mice. In
our study, the hamster model was used and run for 16 days post-
infection during which purified ovine antibodies against TcdA
and TcdB were given for the first 4 days post-challenge only. The
highly toxigenic ATCC 43255 strain of C. difficile produces high
concentrations of TcdA and TcdB in vitro (Merrigan et al., 2010).
The strain described by Merrigan et al. (2010) and the strain used
in these studies was obtained from the same original source. With
all these differences in methodology, it is unwise to compare the
studies in detail. However, both studies support the hypothesis
that toxin neutralizing antibodies can be delivered orally and
prevent CDI in an animal model. It should also be noted that
recently a variant strain of C. difficile, producing only TcdA
was isolated from humans (Marvaud et al., 2019), suggesting
that antibodies that neutralize TcdA might be beneficial in CDI
immune therapeutics.
CONCLUSION
OraCAb demonstrated potential to prevent CDI, induced by a
highly toxigenic C. difficile strain, in the hamster model. A 3:1
ratio of anti-TxB4 IgG to anti-TxA4 IgG with a total IgG
concentration of greater than 50 mg/ml IgG was required for
protection of hamsters. In addition, using the in vitro gut model,
it was proposed that OraCAb antibodies might be beneficial when
used alongside vancomycin to prevent simulated recurrent CDI.
It is important to note that this in vitro model is limited to
the microbiota of the gut, and cannot model some important
factors in CDI, such has host immune response. It is likely
that a treatment that prevents toxin (the disease causing agent)
from acting on the gut mucosa in the first instance could allow
(a) recovery of the microbiota to reduce further C. difficile
growth (b) action of the immune system to reduce the burden
of C. difficile. Clearly, clinical trials are required to answer
such issues surrounding the capacity of orally administered
antibodies to interrupt CDI/gut inflammation. With the pre-
clinical development of OraCAb completed, the formulation
needs to undergo a Phase1b/2a clinical trial where will be tested
for its safety and efficacy. The pre-clinical results presented here
could be used as guidance for the design of antibody ratio and
concentrations in OraCAb that will be used in clinical trials and
subsequent product manufacture.
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